That is correct. Up to now, 5.2 million people have started therapy. Our goal is to double that number so that people will be treated sooner. At the moment, people in Africa are not treated the same as people elsewhere. In Africa, they wait for people's immune system to be really compromised. We now understand that, if we wait for too long, even if we succeed in bringing down the person's viral load, the life expectancy will not be the same as if we had started earlier. So, to be fair, we would like people in developing countries to have access to treatment earlier.
That means that we would have to almost double the number of people being treated. But we have already started to see problems of access to the medication in Tanzania and Uganda, because suppliers are no longer able to provide the required quantities so that the medication is on the market on time.